



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

# **CPRIT University Advisory Committee: 2024 Annual Report**

**CPRIT Oversight Committee Meeting  
May 15, 2024**

**Carlos Arteaga, M.D., Chair**



**Carlos L. Arteaga, M.D.**

Chair 2023- 2025

The University of Texas Southwestern Medical Center

**Subhash C. Chauhan, Ph.D.**

Vice Chair, 2023- 2025

The University of Texas Rio Grande Valley

**Abbey B. Berenson, M.D., MMS, Ph.D.**

The University of Texas Medical Branch at Galveston

**Peter Davies, M.D., Ph.D.**

Texas A&M Health Science Center

**Giulio F. Draetta, M.D., Ph.D.**

The University of Texas MD Anderson Cancer Center

**Joseph “Joe” Heppert, Ph.D.**

Texas Tech University

**Shreek Mandayam, Ph.D.**

Texas State University

**Claudia Neuhauser, Ph.D.**

University of Houston/University of Houston System

**Ramamoorthy Ramesh, Ph.D.**


Rice University

**Pavan Reddy, M.D.**

Baylor College of Medicine

## UAC Membership - broad representation

- Institutional Representatives- senior administrative leaders, Cancer Center Directors
- Health-related Institutions and Academic Campuses
- Active researchers – CPRIT Scholars and funded investigators
- Regional representation



# UAC Meetings – 2023/2024

## March 31, 2023

- Chair and Vice Chair nominations and vote.
  - ✓ Dr. Carlos Arteaga - Chair
  - ✓ Dr. Subhash C. Chauhan - Vice Chair

## April 4, 2024

- Discussed Recruitment FY25.1 RFAs in relation to budget allocation and number of cycles
- Discussed posted FY25.1 RFA Mechanisms
- Discussed potential FY25.2 RFA Mechanisms

## **Focus of Discussion**

- **Recruitment Program**
- **Individual Investigator Research Awards (IIRA) Program**
- **Return on Investment for funding mechanisms**

# Table 1: FY24 Academic Research Program Data Funding Information

Cycle	Mechanism	No. of Applications Submitted	Total Funding Requested	No. of Applications Recommended	Total Funding Recommended by SRC	Success Rate
24.1	Individual Investigator Research Awards (IIRA)	227	\$233,894,288	32	\$33,340,622	14%
	IIRA for Children and Adolescents	35	\$47,815,216	6	\$8,398,170	17%
	IIRA for Clinical Translation	16	\$19,850,946	3	\$5,921,344	19%
	IIRA for Computational & Systems Biology	18	\$36,108,737	3	\$3,599,999	17%
	IIRA for Prevention and Early Detection	15	\$27,050,403	1	\$1,920,007	7%
<sup>1</sup> 24.1	<b>IIRA Totals</b>	<b>294</b>	<b>\$364,719,590</b>	<b>45</b>	<b>\$53,180,142</b>	<b>15%</b>
	*Recruitment of Established Investigators	8	\$47,997,619	5	\$30,000,000	63%
	Recruitment of Rising Stars	13	\$50,000,000	4	\$16,000,000	31%
	Recruitment of First-Time, Tenure Track	25	\$49,988,639	12	\$23,988,639	48%
	<b>Recruitment Totals</b>	<b>46</b>	<b>\$147,986,258</b>	<b>22</b>	<b>\$69,998,639</b>	<b>48%</b>
<b>FY24.1 Totals</b>						

- 1 FY 24.2: This cycle is currently in peer review. The Oversight Committee will review SRC/PIC recommendations in August 2024.
2. One SRC recommended Rising Star candidate withdrew prior to the Program Integration Committee meeting

## Summary of FY24 measures implemented to align budget

1. Reduced recruitment cycles from 12 to 9

## Table 2: Research RFAs by Mechanism, Award Funding, Return on Investment

RFA	No. of Awards	Award Funding (Million)	Follow-On Funds (Million)	Patents Filed	Pubs	No. of Clinical Trials	No. of Patients Enrolled
Individual Investigator Research Awards (IIRA)*	528	\$496	\$471	86	1715	35	4,465
IIRA for Children and Adolescents	61	\$81	\$26	7	145	9	1,527
IIRA for Clinical Translation	17	\$32	\$2	0	62	13	1,198
IIRA for Computational Systems Biology	17	\$17	\$2	4	4	0	0
IIRA for Prevention and Early Detection	36	\$49	\$11	4	4	4	11,824
<b>Total</b>	<b>659</b>	<b>\$675</b>	<b>\$512</b>	<b>101</b>	<b>1930</b>	<b>61</b>	<b>19,014</b>

\* IIRAs initiated in 2010; the four targeted IIRAs were initiated between 2015-2018

**Table 3: Special Research RFAs by Mechanism, Award Funding, and Return on Investment**

<b>RFA</b>	<b>No. of Awards</b>	<b>Award Funding (Million)</b>	<b>Follow-On Funds (Million)</b>	<b>Patents Filed</b>	<b>Pubs</b>	<b>No. of Clinical Trials</b>	<b>No. of Patients Enrolled</b>
Core Facility	73	\$304	\$1,322	48	1661	44	6552
High-Impact, High Risk	223	\$47	\$80	40	387	7	819
Multi-Investigator	36	\$278	\$298	33	820	31	1502
<b>Total</b>	<b>332</b>	<b>\$629</b>	<b>\$1,700</b>	<b>121</b>	<b>2868</b>	<b>82</b>	<b>8873</b>

Source: Annual Progress Reports, Self-Reported Data by Scholars


**Table 4: Recruitment of Scholars by Mechanism, Award Funding, Return on Investment**

<b>RFA</b>	<b>Accepted</b>	<b>Award Funding (Million)</b>	<b>Follow-On Funds (Million)</b>	<b>Patents Filed</b>	<b>Pubs</b>	<b>No. of Clinical Trials</b>	<b>No. of Patients Enrolled</b>
Established Investigator	64	\$356	\$400	215	1148	38	5438
Rising Star	32	\$110	\$103	5	435	12	1800
First-Time, Tenure Track	217	\$426	\$459	58	1274	10	1741
<b>Total</b>	<b>313</b>	<b>\$892</b>	<b>\$958</b>	<b>278</b>	<b>2857</b>	<b>60</b>	<b>8979</b>

Source: Annual Progress Reports, Self-Reported Data by Scholars

# CPRIT Scholars Program – A Jewel in the Crown of the Academic Research Program

- Unique Program building human capacity for cancer research across the State of Texas
- Major impact on cancer research programs in both health-related and academic institutions statewide
- Over last 13 years, steady increase in number of scholar awards, primarily in 1<sup>st</sup> Time recruiting awards Figure 1






## Table 8: FY25 Recruitment Cycles – Model 2 for Budget Alignment

Current Schedule for Recruitment Cycles				Revised Schedule		
Review Cycle	Cycle Closes	Oversight Cmte Review	Potential Award Date	Review Cycle	Model 2	Proportion of Rec. Funds
25.1	7/20/24	11/20/24	12/1/24	25.1		
25.2	8/20/24	11/20/24	12/1/24	25.2	8/20/24	
25.3	9/20/24	11/20/24	12/1/24	25.3		
25.4	10/20/24	2/19/25	3/1/25	25.4	10/20/24	~25%
25.5	11/20/24	2/19/25	3/1/25	25.5	11/20/24	
25.6	12/20/24	2/19/25	3/1/25	25.6		
25.7	1/20/25	5/21/25	6/1/25	25.7	1/20/25	25-30%
25.8	2/20/25	5/21/25	6/1/25	25.8	2/20/25	
25.9	3/20/25	5/21/25	6/1/25	25.9	3/20/25	
25.10	4/20/25	8/20/25	9/1/25	25.10	4/20/25	45-50%
25.11	5/20/25	8/20/25	9/1/25	25.11	5/20/25	
25.12	6/20/25	8/20/25	9/1/25	25.12	6/20/25	

Of the models considered, the consensus of the UAC was that Model 2 was the best for institutions

# Table 9: Recruitment Submissions, Recommended Totals and Success Rate by Year and Gender FY14-FY24

Fiscal Year	No. of Submissions		No. of Recommended		Success Rate	
	Male	Female	Male	Female	Male	Female
2014	32	11	16	6	50.0%	54.5%
2015	45	15	25	9	55.6%	60.0%
2016	56	16	28	8	50.0%	50.0%
2017	50	15	28	6	56.0%	40.0%
2018	46	15	25	5	54.3%	33.3%
2019	53	33	30	17	56.6%	51.5%
2020	61	23	29	7	47.5%	30.4%
2021	37	27	24	15	64.9%	55.6%
2022	50	26	30	13	60.0%	50.0%
2023	31	10	17	5	54.8%	50.0%
2024	32	14	15	7	46.9%	50.0%
<b>Total</b>	<b>493</b>	<b>205</b>	<b>267</b>	<b>98</b>	<b>54.2%</b>	<b>47.8%</b>



**Table 10: Submissions, Recommended and Success Rate Totals by Mechanism and Gender (FY14-FY24)**

Mechanism	No. of Submissions		No. Recommended		Success Rate	
	Female	Male	Female	Male	Female	Male
Established Investigators	32	117	12	63	37.5%	53.8%
Rising Star	40	84	14	33	35.0%	39.3%
First-Time, Tenure Track	133	292	72	171	54.1%	58.6%

# The Value Proposition

**An Economic assessment of the Cost of Cancer in Texas and the Benefits of the Cancer Prevention and Research Institute of Texas (CPRIT) and its Programs: 2023 Update**

**THE PERRYMAN GROUP**

*Reducing the burden of cancer provides benefits to individuals, families, hospitals, state and local governments, insurance providers, and society as a whole.*

*In addition to their positive effect on health and wellbeing, CPRIT activities generate sizable economic benefits.*

**Every \$1 spent through CPRIT for screening/prevention saves \$2.05 in direct health spending and leads to a total of \$27.82 in treatment cost savings and resulting economic benefits through earlier detection.**

*The total economic benefits of CPRIT operations, prevention/screening programs, research, outcomes-based prevention/screening, and secondary research effects was found to include almost \$23.8 billion in output each year, and 201,911 jobs (including multiplier effects).*

# 2024 Recommendations

- Scholar Recruitment RFAs (Reduce to 9 cycles to accommodate budget and institutions recruitment schedules)
- Core Facility Support RFAs
- Clinical Trial Focused RFAs
- Research Training RFAs
- RFAs targeted to TREC-eligible institutions
- RFA focusing on emergent cancers impacting Texans

# Summary and Conclusions

- The Covid catastrophe has provided an important opportunity to take stock of priorities and recalibrate existing programs as well as new programs to leverage the accomplishments of the last 16 years in charting a new course for the future.
- From the UAC perspective, the Academic Research Program is a remarkable accomplishment – a stable, valuable program supporting all aspects of cancer research in Texas.
- The academic research community, through the UAC, expresses its gratitude to the leadership of CPRIT for their support and the very inclusive approach they have taken to engage the opinion of key stakeholders in the research enterprise.

**Thank You**